Search Results 911-920 of 18976 for Neutrophil

1. A Study Using the New TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients with Metastatic, Persistent, Recurrent, or Progressive Solid Tumors - Mayo Clinic

   Absolute neutrophil count (ANC) >= 1400/mm^3; Platelets (PLT) >= 100,000/mm^3; Lymphocytes >= 700/mm^3; Hemoglobin >= 10 g/dL; Total bilirubin =< 1.5 X upper ...

2. Belumosudil in Subjects with Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

   Participation eligibility · Absolute neutrophil count ≥ 1.5 × 109 /L; · Platelet count ≥ 100 × 109 /L; · Total bilirubin ≤ 1.0 × upper limit of normal (ULN); ...

3. A Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT) - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1000/mm^3 *without growth factor support;; Platelet count ≥ 50,000/mm^3 (*Untransfused);; PT/INR/aPTT ≤ 1.5 x ULN;; Total ...

4. A Study of RP2 with Nivolumab compared to Ipilimumab with Nivolumab with Metastatic Uveal Melanoma - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1.5 × 109 /L; Platelet count ≥ 100 × 109 /L; Hemoglobin ≥ 8 g/dL (without packed red blood cell [RBC] transfusion within ...

5. Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1,500/mm^3;; Platelet count ≥ 100,000/mm^3;; Creatinine ≤ 1.5 mg/dL OR;; Calculated creatinine clearance ≥ 30 mL/min ...

6. Dual BET And CBP/p300 Inhibitor In Patients With Targeted Advanced Solid Tumors And Hematological Malignancies - Mayo Clinic

   * Absolute neutrophil count (ANC) ≥ 1,500/dL (Part 1) * Platelet count ≥100,000/μL (Part 1) or ≥75,000/μL (Part 3) Adequate renal function: Creatinine ...

7. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL; Hemoglobin ≥ 9 g/dL; Platelets ≥ 100,000/mcL; Total bilirubin ≤ institutional upper limit of normal (ULN); Aspartate ...

8. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

   Absolute neutrophil count ≥ 1.5 x 10^9 cells/L). Adequate cardiac function: Left ventricular ejection fraction (LVEF) of > 50% as assessed by multi-gated ...

9. Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma - Mayo Clinic

   Absolute neutrophil count ≥ 1000/uL; Untransfused platelet count ≥ 75000/uL; Hemoglobin ≥ 8 g/dL; Total bilirubin ≤ 1.5 times institutional upper limit of ...

10. Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer - Mayo Clinic

    Absolute neutrophil count ≥ 1500/mcL;; Hemoglobin ≥ 9.0 g/dL;; Platelets ≥ 100,000/mcL;; Total bilirubin ≤ 1.5 x the upper limit of normal (ULN);; SGPT (ALT) ...